In yesterday’s Wall Street session, Avalo Therapeutics Inc (NASDAQ:AVTX) shares traded at $0.09, up 0.66% from the previous session.
1 analysts cover Avalo Therapeutics Inc (NASDAQ:AVTX), according to research data. The consensus rating among analysts is ‘Hold’. As we calculate the median target price by taking the range between a high of $0.75 and a low of $0.75, we find $0.75. Given the previous closing price of $0.09, this indicates a potential upside of 733.33 percent. AVTX stock price is now -27.50% away from the 50-day moving average and -94.18% away from the 200-day moving average. The market capitalization of the company currently stands at $17.51M.
The stock has received a hold rating from 1 analysts and a buy rating from 0. Brokers who have rated the stock have averaged $0.75 as their price target over the next twelve months.
With the price target of $6, RBC Capital Mkts recently initiated with Outperform rating for Avalo Therapeutics Inc (NASDAQ: AVTX).
In other news, ARMISTICE CAPITAL, LLC, 10% Owner sold 937,404 shares of the company’s stock on Jun 27. The stock was sold for $486,888 at an average price of $0.52. Upon completion of the transaction, the 10% Owner now directly owns 731,458 shares in the company, valued at $65831.22. An SEC document containing details of the transaction can be found on the SEC’s website. On Jun 26, 10% Owner ARMISTICE CAPITAL, LLC sold 2,746,138 shares of the business’s stock. A total of $1,682,010 was realized by selling the stock at an average price of $0.61. This leaves the insider owning 1,668,862 shares of the company worth $0.15 million. Insiders disposed of 2,545,404 shares of company stock worth roughly $0.23 million over the past 1 year. A total of 0.77% of the company’s stock is owned by insiders.
On Monday morning Avalo Therapeutics Inc (NASDAQ: AVTX) stock kicked off with the opening price of $0.0900. During the past 12 months, Avalo Therapeutics Inc has had a low of $0.08 and a high of $6.09. As of last week, the company has a debt-to-equity ratio of 0.14, a current ratio of 2.11, and a quick ratio of 2.11. The fifty day moving average price for AVTX is $0.1256 and a two-hundred day moving average price translates $1.5623 for the stock.
The latest earnings results from Avalo Therapeutics Inc (NASDAQ: AVTX) was released for Sep, 2023. According to the Biotechnology Company, earnings per share came in at -$0.11, beating analysts’ expectations of -$1.1 by 0.99. This compares to $0.34 EPS in the same period last year. The net profit margin was -1475.02% and return on equity was -524.01% for AVTX. The company reported revenue of $0.24 million for the quarter, compared to $14.95 million a year earlier. Comparatively to last year’s same quarter, the company’s quarterly revenue fell -98.42 percent. For the current quarter, analysts expect AVTX to generate $1M in revenue.
Avalo Therapeutics Inc(AVTX) Company Profile
Avalo Therapeutics, Inc., a clinical stage biotechnology company, focuses on the development of therapies for the treatment of immune dysregulation. The company’s drug candidates include AVTX-002, a fully human anti-LIGHT monoclonal antibody, which is under Phase II clinical trial for the treatment of non-eosinophilic asthma, as well as Crohn’s disease; Phase III clinical trial for the treatment of COVID-19 acute respiratory distress syndrome; and AVTX-008, a fully human B and T Lymphocyte Attenuator (BTLA) agonist fusion protein. It also develops AVTX-803, a L-fucose monosaccharide therapy for treatment of Leukocyte Adhesion Deficiency Type II. The company was formerly known as Cerecor Inc. and changed its name to Avalo Therapeutics, Inc. in August 2021. Avalo Therapeutics, Inc. was incorporated in 2011 and is headquartered in Rockville, Maryland.